Swiss National Bank Has $700.84 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Swiss National Bank raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,133,000 shares of the medical research company's stock after acquiring an additional 2,800 shares during the quarter. Thermo Fisher Scientific accounts for about 0.5% of Swiss National Bank's portfolio, making the stock its 29th biggest holding. Swiss National Bank owned 0.30% of Thermo Fisher Scientific worth $700,840,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of TMO. BDF Gestion purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $6,368,000. Nisa Investment Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.2% during the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock worth $87,093,000 after purchasing an additional 8,180 shares during the period. Seven Eight Capital LP purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $1,161,000. Simplify Asset Management Inc. lifted its position in Thermo Fisher Scientific by 67.4% in the 3rd quarter. Simplify Asset Management Inc. now owns 13,770 shares of the medical research company's stock worth $8,518,000 after buying an additional 5,546 shares in the last quarter. Finally, ORG Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 216.6% during the 2nd quarter. ORG Partners LLC now owns 1,640 shares of the medical research company's stock valued at $890,000 after buying an additional 1,122 shares during the period. Institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating on the stock in a research report on Thursday, October 24th. Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Barclays cut their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a research report on Friday, September 20th. Finally, Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $649.33.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 3.7 %

Shares of TMO stock traded down $19.94 on Friday, reaching $513.08. The company had a trading volume of 3,953,117 shares, compared to its average volume of 1,404,541. The company has a 50-day moving average of $586.43 and a 200-day moving average of $582.39. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $196.25 billion, a PE ratio of 32.17, a PEG ratio of 3.39 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12 month low of $464.17 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. During the same quarter in the prior year, the company earned $5.69 EPS. The company's revenue was up .2% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's payout ratio is presently 9.78%.

Thermo Fisher Scientific declared that its board has approved a stock repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.